News

Sanofi outlines high single-digit sales growth for 2025 while advancing innovation pipeline and strategic acquisitions

Sanofi reports strong Q2 2025 growth with innovative launches like Dupixent and strategic acquisitions boosting sales.

Sanofi (SNY) Q2 2025 Earnings Call Transcript

Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsBrian Foard - Executive VP & Head of ...

Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...
Santé log9h

Press release: Online availability of Sanofi’s half-year financial report for 2025

Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des ...

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Sanofi falls after Q2 profit misses despite sales beat on higher costs

Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...
Santé log21h

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...